MARKET

ERNA

ERNA

Ernexa
NASDAQ
1.320
+0.010
+0.76%
After Hours: 1.298 -0.022 -1.66% 19:47 12/05 EST
OPEN
1.300
PREV CLOSE
1.310
HIGH
1.320
LOW
1.201
VOLUME
33.74K
TURNOVER
--
52 WEEK HIGH
14.40
52 WEEK LOW
1.090
MARKET CAP
10.36M
P/E (TTM)
-0.2482
1D
5D
1M
3M
1Y
5Y
1D
ERNEXA THERAPEUTICS ANNOUNCES ORAL PRESENTATION AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING
Reuters · 2d ago
Ernexa Therapeutics appoints Ira Winer to Scientific, Medical Advisory Board
TipRanks · 3d ago
Press Release: Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG
Dow Jones · 3d ago
Weekly Report: what happened at ERNA last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at ERNA last week (1117-1121)?
Weekly Report · 11/24 10:28
Weekly Report: what happened at ERNA last week (1110-1114)?
Weekly Report · 11/17 10:29
Eterna Therapeutics reports Q3 results
Seeking Alpha · 11/10 14:12
Reported November 7, 2025: Ernexa Therapeutics Q3 EPS $(0.15) Up From $(73.70) YoY
Benzinga · 11/10 13:51
More
About ERNA
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.

Webull offers Ernexa Therapeutics Inc stock information, including NASDAQ: ERNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERNA stock methods without spending real money on the virtual paper trading platform.